Biologic agents and tuberculosis

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

15 Citations (Scopus)

Abstract

Treatment with biologic agents, in particular tumor necrosis factor alpha (TNF-α) inhibitors, is associated with an increased risk of tuberculosis (TB), and screening and treatment for latent TB infection (LTBI) in patients undergoing such treatment is therefore indicated. The risk of TB associated with different biologics varies significantly, with the highest relative risks, 29.3 and 18.6, associated with adalimumab and infliximab, respectively. The risk of TB with newer TNF-α inhibitors and other biologics appears to be lower. Performance of LTBI screening tests is affected by immune-mediated inflammatory diseases and immunosuppressive therapy in patients due to commence TNF-α inhibitor treatment. Interferon gamma release assays (IGRAs) have a higher specificity than the tuberculin skin test (TST) in patients with Bacillus Calmette-Guérin (BCG) vaccination and have probably a better sensitivity than TST in immunosuppressed patients. LTBI screening programs prior to commencement of anti-TNF-α treatment significantly reduce the incidence of TB, but the optimal screening algorithm, in particular the question of whether a combination of IGRA and TST or a single test only should be used, is a matter of ongoing debate. Use of TST in combination with IGRA is justified to increase sensitivity. Repeat testing for LTBI should be limited to patients at increased risk of TB. If TB develops during anti-TNF-α treatment, it is more likely to be disseminated and extrapulmonary than are other TB cases. Discontinuation of anti-TNF-α treatment in patients diagnosed with TB is associated with an increased risk of immune reconstitution inflammatory syndrome, which is probably best managed by reintroduction of anti-TNF-α treatment.

Original languageEnglish
Title of host publicationTuberculosis and Nontuberculous Mycobacterial Infections
EditorsDavid Schlossberg
Place of PublicationWashington, DC
PublisherAmerican Society for Microbiology
Chapter37
Pages623-635
Number of pages13
Edition7th
ISBN (Electronic)9781555819866
ISBN (Print)9781555819859
DOIs
Publication statusPublished - 2017
Externally publishedYes

Publication series

NameMicrobiology spectrum
PublisherAmerican Society for Microbiology

Fingerprint

tuberculosis
Biological Factors
Tuberculosis
tumor
Tumor Necrosis Factor-alpha
Tuberculin Test
Interferon-gamma Release Tests
Skin Tests
skin
inhibitor
Therapeutics
assay
Biological Products
Infection
Immune Reconstitution Inflammatory Syndrome
Latent Tuberculosis
vaccination
reintroduction
Immunosuppressive Agents
necrosis

Cite this

Dobler, C. C. (2017). Biologic agents and tuberculosis. In D. Schlossberg (Ed.), Tuberculosis and Nontuberculous Mycobacterial Infections (7th ed., pp. 623-635). (Microbiology spectrum). Washington, DC: American Society for Microbiology. https://doi.org/10.1128/microbiolspec.TNMI7-0026-2016
Dobler, Claudia C. / Biologic agents and tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections. editor / David Schlossberg. 7th. ed. Washington, DC : American Society for Microbiology, 2017. pp. 623-635 (Microbiology spectrum).
@inbook{57cd14f6f7c244fba73cd916e590962c,
title = "Biologic agents and tuberculosis",
abstract = "Treatment with biologic agents, in particular tumor necrosis factor alpha (TNF-α) inhibitors, is associated with an increased risk of tuberculosis (TB), and screening and treatment for latent TB infection (LTBI) in patients undergoing such treatment is therefore indicated. The risk of TB associated with different biologics varies significantly, with the highest relative risks, 29.3 and 18.6, associated with adalimumab and infliximab, respectively. The risk of TB with newer TNF-α inhibitors and other biologics appears to be lower. Performance of LTBI screening tests is affected by immune-mediated inflammatory diseases and immunosuppressive therapy in patients due to commence TNF-α inhibitor treatment. Interferon gamma release assays (IGRAs) have a higher specificity than the tuberculin skin test (TST) in patients with Bacillus Calmette-Gu{\'e}rin (BCG) vaccination and have probably a better sensitivity than TST in immunosuppressed patients. LTBI screening programs prior to commencement of anti-TNF-α treatment significantly reduce the incidence of TB, but the optimal screening algorithm, in particular the question of whether a combination of IGRA and TST or a single test only should be used, is a matter of ongoing debate. Use of TST in combination with IGRA is justified to increase sensitivity. Repeat testing for LTBI should be limited to patients at increased risk of TB. If TB develops during anti-TNF-α treatment, it is more likely to be disseminated and extrapulmonary than are other TB cases. Discontinuation of anti-TNF-α treatment in patients diagnosed with TB is associated with an increased risk of immune reconstitution inflammatory syndrome, which is probably best managed by reintroduction of anti-TNF-α treatment.",
author = "Dobler, {Claudia C.}",
year = "2017",
doi = "10.1128/microbiolspec.TNMI7-0026-2016",
language = "English",
isbn = "9781555819859",
series = "Microbiology spectrum",
publisher = "American Society for Microbiology",
pages = "623--635",
editor = "David Schlossberg",
booktitle = "Tuberculosis and Nontuberculous Mycobacterial Infections",
address = "United States",
edition = "7th",

}

Dobler, CC 2017, Biologic agents and tuberculosis. in D Schlossberg (ed.), Tuberculosis and Nontuberculous Mycobacterial Infections. 7th edn, Microbiology spectrum, American Society for Microbiology, Washington, DC, pp. 623-635. https://doi.org/10.1128/microbiolspec.TNMI7-0026-2016

Biologic agents and tuberculosis. / Dobler, Claudia C.

Tuberculosis and Nontuberculous Mycobacterial Infections. ed. / David Schlossberg. 7th. ed. Washington, DC : American Society for Microbiology, 2017. p. 623-635 (Microbiology spectrum).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Biologic agents and tuberculosis

AU - Dobler, Claudia C.

PY - 2017

Y1 - 2017

N2 - Treatment with biologic agents, in particular tumor necrosis factor alpha (TNF-α) inhibitors, is associated with an increased risk of tuberculosis (TB), and screening and treatment for latent TB infection (LTBI) in patients undergoing such treatment is therefore indicated. The risk of TB associated with different biologics varies significantly, with the highest relative risks, 29.3 and 18.6, associated with adalimumab and infliximab, respectively. The risk of TB with newer TNF-α inhibitors and other biologics appears to be lower. Performance of LTBI screening tests is affected by immune-mediated inflammatory diseases and immunosuppressive therapy in patients due to commence TNF-α inhibitor treatment. Interferon gamma release assays (IGRAs) have a higher specificity than the tuberculin skin test (TST) in patients with Bacillus Calmette-Guérin (BCG) vaccination and have probably a better sensitivity than TST in immunosuppressed patients. LTBI screening programs prior to commencement of anti-TNF-α treatment significantly reduce the incidence of TB, but the optimal screening algorithm, in particular the question of whether a combination of IGRA and TST or a single test only should be used, is a matter of ongoing debate. Use of TST in combination with IGRA is justified to increase sensitivity. Repeat testing for LTBI should be limited to patients at increased risk of TB. If TB develops during anti-TNF-α treatment, it is more likely to be disseminated and extrapulmonary than are other TB cases. Discontinuation of anti-TNF-α treatment in patients diagnosed with TB is associated with an increased risk of immune reconstitution inflammatory syndrome, which is probably best managed by reintroduction of anti-TNF-α treatment.

AB - Treatment with biologic agents, in particular tumor necrosis factor alpha (TNF-α) inhibitors, is associated with an increased risk of tuberculosis (TB), and screening and treatment for latent TB infection (LTBI) in patients undergoing such treatment is therefore indicated. The risk of TB associated with different biologics varies significantly, with the highest relative risks, 29.3 and 18.6, associated with adalimumab and infliximab, respectively. The risk of TB with newer TNF-α inhibitors and other biologics appears to be lower. Performance of LTBI screening tests is affected by immune-mediated inflammatory diseases and immunosuppressive therapy in patients due to commence TNF-α inhibitor treatment. Interferon gamma release assays (IGRAs) have a higher specificity than the tuberculin skin test (TST) in patients with Bacillus Calmette-Guérin (BCG) vaccination and have probably a better sensitivity than TST in immunosuppressed patients. LTBI screening programs prior to commencement of anti-TNF-α treatment significantly reduce the incidence of TB, but the optimal screening algorithm, in particular the question of whether a combination of IGRA and TST or a single test only should be used, is a matter of ongoing debate. Use of TST in combination with IGRA is justified to increase sensitivity. Repeat testing for LTBI should be limited to patients at increased risk of TB. If TB develops during anti-TNF-α treatment, it is more likely to be disseminated and extrapulmonary than are other TB cases. Discontinuation of anti-TNF-α treatment in patients diagnosed with TB is associated with an increased risk of immune reconstitution inflammatory syndrome, which is probably best managed by reintroduction of anti-TNF-α treatment.

UR - http://www.scopus.com/inward/record.url?scp=85011695917&partnerID=8YFLogxK

U2 - 10.1128/microbiolspec.TNMI7-0026-2016

DO - 10.1128/microbiolspec.TNMI7-0026-2016

M3 - Chapter

SN - 9781555819859

T3 - Microbiology spectrum

SP - 623

EP - 635

BT - Tuberculosis and Nontuberculous Mycobacterial Infections

A2 - Schlossberg, David

PB - American Society for Microbiology

CY - Washington, DC

ER -

Dobler CC. Biologic agents and tuberculosis. In Schlossberg D, editor, Tuberculosis and Nontuberculous Mycobacterial Infections. 7th ed. Washington, DC: American Society for Microbiology. 2017. p. 623-635. (Microbiology spectrum). https://doi.org/10.1128/microbiolspec.TNMI7-0026-2016